On December 20, 2019, Parent Project Muscular Dystrophy (PPMD) and World Duchenne Organization (WDO) hosted an informational webinar with the Wave Life Sciences team to discuss their decision to discontinue development of suvodirsen for patients with Duchenne who have mutations amenable to exon 51 skipping, as well as suspending further development of WVE-N531, their candidate for individuals with Duchenne who have mutations amenable to exon 53 skipping.